Sugi Predict

Sugi Predict / Compounds / SCHEMBL1711292

SCHEMBL1711292

SCHEMBL1711292

CC(C)C[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CPB2 Q96IY4 7/20 0.49
▸ FOLH1 Q04609 5/20 0.49
▸ ERAP2 Q6P179 1/20 0.48
▸ ERAP1 Q9NZ08 1/20 0.48
▸ LNPEP Q9UIQ6 1/20 0.48
▸ NOD1 Q9Y239 1/20 0.48
▸ OPRK1 P41145 1/20 0.43
▸ NPY1R P25929 1/20 0.43
▸ NPY2R P49146 1/20 0.43
▸ NPY4R P50391 1/20 0.43
▸ NMT2 O60551 1/20 0.43
▸ NMT1 P30419 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ SLC6A5 Q9Y345 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711530 1.00 CPB2 (0.49) CPB2FOLH1ERAP2ERAP1LNPEP
SCHEMBL1711525 1.00 CPB2 (0.49) CPB2FOLH1ERAP2ERAP1LNPEP
SCHEMBL1711286 1.00 CPB2 (0.49) CPB2FOLH1ERAP2ERAP1LNPEP
SCHEMBL30512557 1.00 CPB2 (0.49) CPB2FOLH1ERAP2ERAP1LNPEP
SCHEMBL29630784 0.99 CPB2 (0.48) CPB2FOLH1ERAP2ERAP1LNPEP
SCHEMBL29398435 0.94 CPB2 (0.46) CPB2FOLH1ERAP2ERAP1LNPEP
SCHEMBL30496431 0.94 CPB2 (0.45) CPB2FOLH1ERAP2ERAP1LNPEP
SCHEMBL11644217 0.91 FOLH1 (0.54) CPB2FOLH1ERAP2ERAP1LNPEP
SCHEMBL11644225 0.91 FOLH1 (0.54) CPB2FOLH1ERAP2ERAP1LNPEP
SCHEMBL1711242 0.91 FOLH1 (0.57) CPB2FOLH1ERAP2ERAP1LNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113423422-B Proliferation method 花王株式会社 2024-05-10 — — CN claimed
CN-116096363-A Coronavirus proliferation method 花王株式会社 2023-05-09 — — CN claimed
CN-113423422-B Proliferation method 花王株式会社 2024-05-10 — — CN disclosed
WO-2023212662-A2 COMPOSITIONS AND METHODS FOR MODULATING ANTIGEN BINDING ACTIVITY OREGON HEALTH & SCIENCE UNIVERSITY (US) 2023-11-02 — — WO disclosed
CN-116096363-A Coronavirus proliferation method 花王株式会社 2023-05-09 — — CN disclosed
US-11419944-B2 Non-linear self-immolative linkers and conjugates thereof BYONDIS B.V. (NL) 2022-08-23 — — US disclosed
US-11052155-B2 Conjugates of CC-1065 analogs and bifunctional linkers SYNTARGA BV (NL) 2021-07-06 — — US disclosed
US-20200297859-A1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF BYONDIS B.V. (NL) 2020-09-24 — — US disclosed
EP-3525826-B1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF BYONDIS BV (NL) 2020-07-22 — — EP disclosed
EP-3108886-B1 CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS SYNTARGA BV (NL) 2020-06-17 — — EP disclosed
EP-3525826-A1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF Synthon Biopharmaceuticals B.V. (NL) 2019-08-21 — — EP disclosed
WO-2010062171-A2 NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES SYNTARGA B.V. (NL) 2010-06-03 — — WO disclosed
EP-2173739-A1 SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES Syntarga B.V. (NL) 2010-04-14 — — EP disclosed
US-20090318668-A1 Water-Soluble CC-1065 Analogs and Their Conjugates Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) 2009-12-24 — — US disclosed
WO-2009017394-A1 SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES SYNTARGA B.V. (NL) 2009-02-05 — — WO disclosed
US-20080311136-A1 Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation BYONDIS B.V. (NL) 2008-12-18 — — US disclosed
EP-1994000-A2 WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES Syntarga B.V. (NL) 2008-11-26 — — EP disclosed
EP-1909846-A2 TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES THEREOF, AND METHODS OF PREPARATION Syntarga B.V. (NL) 2008-04-16 — — EP disclosed
WO-2007089149-A2 WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES SYNTARGA B.V. (NL) 2007-08-09 — — WO disclosed
WO-2007018431-A2 TRIAZOLE-CONTAINING RELEASABLE LINKERS AND CONJUGATES COMPRISING THE SAME SYNTARGA B.V. (NL) 2007-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318668-A1 Water-Soluble CC-1065 Analogs and Their Conjugates PCNA, DCK, BAD CPB2 2100/4885FOLH1 1106/4885ERAP2 3834/4885
US-20200297859-A1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF DLST, ADSL, LANCL1 CPB2 3797/4885FOLH1 736/4885ERAP2 4123/4885
US-20080311136-A1 Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation PAICS, CD44, TRIM33 CPB2 1403/4885FOLH1 90/4885ERAP2 3376/4885
US-11052155-B2 Conjugates of CC-1065 analogs and bifunctional linkers PCNA, DCLRE1A, CDC5L CPB2 1600/4885FOLH1 603/4885ERAP2 2981/4885
US-11419944-B2 Non-linear self-immolative linkers and conjugates thereof DLST, ADSL, LANCL1 CPB2 3797/4885FOLH1 736/4885ERAP2 4123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.